The $3 billion fine recently leveled against GlaxoSmithKline is the largest settlement ever involving a pharmaceutical company. But in light of the enormous profits that the British pharmaceutical giant brings in, some critics wonder whether even that will be enough to dissuade companies from engaging in dangerous fraud.
GlaxoSmithKline pleaded guilty to marketing drugs for unapproved uses, according to a New York Times report. Among the charges is that the company ...
continue reading...
In a piece for the Wall Street Journal, writer Katherine Sharpe argues that antidepressants are overprescribed in the United States, and discusses the challenges that face a growing segment of population – young people who have no conception of who they are when they aren’t on antidepressants.
She cites figures from the National Center for Health Statistics, which state that 5 percent of American 12- to 19-year-olds use antidepressants, and another ...
continue reading...GlaxoSmithKline has agreed to pay $3 billion in fines for fraudulently promoting medications for unapproved uses. According to a New York Times report, it’s the largest settlement ever leveled against a pharmaceutical company.
But the settlement doesn’t end the company’s legal disputes. Widespread lawsuits allege that GlaxoSmithKline and other manufacturers of antidepressants classified as selective serotonin reuptake inhibitors failed to adequately warn pregnant patients of studies linking the drugs to continue reading...
U.S. Senator Charles Schumer of New York is calling for a nationwide effort to combat the problem of babies born addicted to prescription painkillers or other opiates, known as Neonatal Abstinence Syndrome (NAS).
In a news release on the issue, Schumer cites a study published in the Journal of the American Medical Association (JAMA), which found that approximately 3.4 of every 1,000 infants born in 2009 suffered from NAS. That amounts ...
continue reading...
Women are more likely than males to take antidepressants, according to the national Centers for Disease Control and Prevention.
That information was part of the CDC’s National Health and Nutrition Examination Surveys for the years 2005 to 2008.
Among the findings:
In an interview with Metro New York, author Katherine Sharpe discusses some of the reasons behind what she sees as a widespread trend among American medical professionals to overprescribe antidepressants.
Sharpe is the author of Coming of Age on Zoloft, which deals with the experiences of young people trying to figure out who they are after spending their formative years on antidepressants.
When antidepressants first came onto the market, medical professionals tended ...
continue reading...
